Boehringer Ingelheim successfully concluded the purchase of Fort Dodge cattle vaccines for its Mexican business
Ingelheim, Germany, 10 August 2010 - Boehringer Ingelheim, a global pharmaceutical group of companies, together with its U.S. animal health business, Boehringer Ingelheim Vetmedica, Inc., announced today that they successfully concluded the purchase of certain Fort Dodge cattle vaccines for Boehringer Ingelheim Vetmedica Mexico. This transaction is part of the acquisition of significant assets of Fort Dodge Animal Health in 2009 and will considerably strengthen the cattle product portfolio of Boehringer Ingelheim Vetmedica Mexico.
In 2009, Boehringer Ingelheim, together with its U.S. animal health business, acquired a significant portion of the Fort Dodge Animal Health business. The acquisition, which included products in the U.S., Australia, Canada and South Africa, as well as two manufacturing and research facilities located in Fort Dodge, Iowa, increased the size of Boehringer Ingelheim's companion animal and cattle portfolios and strengthened the company's position as a leading animal vaccine supplier.
The acquired portfolio in Mexico includes the following well known brands: Presponse®HM, Pyramid® 5, Triangle® 4 (+type 2 BVD), Triangle® 9 + HS and Triangle® 9 (+ type 2 BVD). The products will continue to reflect the familiar trademarks. The Managing Director of Boehringer Ingelheim Animal Health in Mexico, Dr. Francisco Escudero, commented: “Boehringer Ingelheim is pleased to add these important and popular vaccines to our product portfolio. We are committed to continue providing our cattle customers with a comprehensive package of solutions and services.”
The Boehringer Ingelheim group is one of the world’s 15 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2009, Boehringer Ingelheim posted net sales of 12.7 billion euro while spending 21% of net sales in its largest business segment Prescription Medicines on research and development.